A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Phase 2
38
about 4.2 years
18+
1 site in OH
What this study is about
This trial is testing a new treatment, NovoTTF-200T(P), when combined with gemcitabine and nab-paclitaxel for people with resectable pancreatic cancer. Patients will receive these treatments in cycles followed by surgery to remove the tumor if possible. The goal is to see how well this combination works.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Gemcitabine
- 2.Take Nab paclitaxel
- 3.Use NovoTTF-200T(P)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
injection (Injection), infusion
Primary: 2 Year Overall Survival (OS)
Secondary: Assess adverse events, Overall Response Rate (ORR), Overall Survival (OS), Post Resection Disease Free Survival (DFS)
therapeutic
Oncology